Horizon Discovery Group plc acquires Sage Labs Inc. for $48M (£29M)
Horizon Discovery Group plc, the international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines, today announced it has agreed to acquire Sage Labs Inc. (Sage) for up to $16M (£9.8M) in cash and up to $32M (£19.6M) through the issue of new ordinary shares. The acquisition makes Horizon the world…
Horizon Discovery Group plc signs $1.2 million Master Services Agreement
Horizon Discovery Group plc, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announces that its business unit Horizon Diagnostics has signed a Master Services Agreement with a major global diagnostic development company and a US biopharmaceutical company to support the development of companion diagnostics for novel,…
Horizon Discovery reports a strong first half, positioning for continued growth
Horizon Discovery Group plc (LSE: HZD), the international life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, today announces its interim results for the six months ended 30 June 2014.
Horizon Discovery adds three eminent CRISPR experts to its Scientific Advisory Board
Horizon Discovery Group plc, the international life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, today announced three of the world’s leading gene editing scientists have joined the company’s Scientific Advisory Board (SAB). The scientists are Dr Emmanuelle Charpentier, Dr Keith Joung and Dr Feng Zhang.
Horizon Discovery and Otsuka Pharmaceutical Development and Commercialization to collaborate
Horizon Discovery Group plc, a leading provider of research tools to support translational genomics and the development of personalised medicines, today announced its Horizon CombinatoRx division has been contracted by Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) to perform in vitro cell line screening of certain OPDC development candidate(s). Pursuant to the terms of the…
Horizon Discovery reports strong performance
Horizon Discovery Group plc, the international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines, reports that revenue for the six month period to 30 June 2014 was £4.06 million, 36 per cent ahead of the equivalent period in the prior year (six months to 30 June 2013: £2.98 million) in line with…
Horizon Discovery licenses AAV gene delivery technology from Stanford University
Horizon Discovery™ Group plc, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has entered into a non-exclusive license agreement with Stanford University to access intellectual property related to the use of a proprietary serotype of AAV (Adeno-Associated Virus) for commercial applications involving…
Horizon Discovery wins European Mediscience’s Emerging Star Award 2014
Horizon Discovery Group plc, the international life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, is delighted to announce that it has won the “Emerging Star” category at last night’s (Thursday's) European Mediscience Awards in London.
Horizon Discovery and LGC awarded grant for next generation cancer diagnostics
Improving minimally invasive circulating DNA diagnostic assays supports implementation of stratified and personalized intervention strategies.
Horizon Discovery licenses CRISPR gene editing technology from the Broad Institute
Horizon Discovery™ Group plc, the international life science company supplying research tools to organizations engaged in genomics research and the development of personalized medicines, today announced it has entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system.
Horizon Discovery strengthens Board with appointment of Non-Executive Directors
Horizon Discovery™ Group plc, the international life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, today announces the appointment of Dr. Susan Galbraith, Senior Vice President and Head of Oncology Innovative Medicines at AstraZeneca, and Susan Searle, co-founder and ex-CEO of Imperial Innovations Group plc,…
Horizon completes acquisition of CombinatoRx service business and assets from Zalicus Inc.
The acquisition of a revenue generating and complementary business establishes Horizon’s headquarters in North America.
Horizon Discovery Group plc to acquire CombinatoRx service business from Zalicus Inc.
In a deal worth nearly £5 milllion, Horizon Discovery Group plc today announced it has agreed to acquire the CombinatoRx service business (known as the combination high throughput screening (cHTS) business) and related assets from Zalicus Inc., a biopharmaceutical company. The new business will become Horizon CombinatoRx Incorporated, a wholly owned subsidiary of Horizon.
Horizon Discovery licenses CRISPR/Cas9 gene editing technology from ERS Genomics
Horizon Discovery™ Group plc, the international life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, today announced it has entered into a non-exclusive licence agreement with ERS Genomics Ltd to access intellectual property (IP) relating to the CRISPR/Cas9 gene editing system.
Horizon Discovery launches new gene editing tools and services
Horizon Discovery™ Group plc (LSE: HZD), the life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, today announced the launch of its full range of GENASSIST™ gene editing kits, reagents and support services that enable easier, robust implementation of gene editing experiments with CRISPR and rAAV.
First day of dealings on AIM for Horizon Discovery Group plc
Horizon Discovery Group plc, the life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, is delighted to announce its flotation today on the London Stock Exchange’s AIM market. Horizon’s listing is the largest in terms of funds raised by any Cambridge cluster biotech on AIM, and will ensure its longevity and status…
Horizon Discovery Group plc raises £68.6 million
Horizon Discovery Group plc, the revenue generating life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, is to be admitted to AIM with a market capitalisation of £120.5 million.
Horizon Discovery Group plc announces intention to float
Horizon Discovery Group plc, the revenue generating life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, announces its intention to launch an initial public offering of ordinary shares on the AIM market of the London Stock Exchange. The new share offer raising £25 million will be used to expand the company's…
Horizon Discovery signs supply and distribution agreement with Sirion Biotech GmbH
Horizon Discovery™, a leading provider of research tools to support translational genomics and the development of personalized medicines, announced it has signed a supply and distribution agreement with Sirion Biotech GmbH. The agreement adds custom and off-the-shelf shRNA and cDNA expression capabilities to Horizon’s offering.
Horizon Discovery signs distribution agreement with Haplogen
Horizon will market and distribute haploid gene trap mutant collection to its global customer base.
Horizon Discovery launches kits and reagents for gene-editing
Horizon Discovery™, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has launched the first products and services from its new GENASSIST™ range of gene editing kits and reagents that enable easier, robust implementation of CRISPR and rAAV gene editing experiments.
Horizon Discovery signs large-scale licence agreement for its X-MAN cell lines in Japan
Horizon Discovery™, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has entered into a large-scale licensing agreement with a Japanese medical university.
Horizon Discovery and Transgenomic collaborate to develop genetic diagnostic tests
Transgenomic will use Horizon’s genetically defined reference standards in place of plasmid-derived controls.
Dr Ian Gilham appointed Chairman of the Board for Horizon Discovery
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, today announced the formal appointment of Dr Ian Gilham as Chairman of its Board of Directors.
Horizon Discovery announces new oncology research and collaboration with AstraZeneca
Horizon Discovery and AstraZeneca have entered into a research, collaboration and licence agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets.